By: IPP Bureau
Last updated : August 26, 2025 9:46 am
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Merck, known as MSD outside the U.S. and Canada, will present new clinical trial and outcomes research data at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain, from August 29 – September 1. The data highlight Merck’s research in atherosclerotic cardiovascular disease (ASCVD), pulmonary hypertension (PH), and heart failure with reduced ejection fraction.
“Cardiovascular disease remains the leading cause of death worldwide, and Merck is committed to addressing this urgent public health challenge through research and innovative science,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “At this year’s congress, the data we are presenting reflect our continued commitment to advancing cardiovascular research with the goal of improving outcomes for patients at risk around the world.”
Merck will share two oral presentations on ASCVD treatment patterns and patient burden. One presentation evaluates the clinical and economic impact on patients with and without myocardial infarction using a nationwide 10-year registry. The second reviews trends in lipid-lowering therapy use among patients with ASCVD. These studies highlight opportunities for better disease management in real-world settings.
Key updates will also be presented on WINREVAIR in pulmonary hypertension. This includes the rationale and design of the Phase 2 CADENCE study in adults with combined post- and precapillary PH linked to heart failure with preserved ejection fraction (HFpEF), and results from the ZENITH trial evaluating WINREVAIR’s effect on hemodynamics in high-risk pulmonary arterial hypertension (PAH).
In addition, Merck will present new data on VERQUVO (vericiguat) for adults with HFrEF, including two hot line oral presentations and two poster presentations from the VICTOR and VICTORIA trials, as well as real-world analyses.